High S100B Levels Predict Antidepressant Response in Patients With Major Depression Even When Considering Inflammatory and Metabolic Markers.
HDL-cholesterol
S100B protein
antidepressant
major depression
reactive-C protein
Journal
The international journal of neuropsychopharmacology
ISSN: 1469-5111
Titre abrégé: Int J Neuropsychopharmacol
Pays: England
ID NLM: 9815893
Informations de publication
Date de publication:
21 06 2022
21 06 2022
Historique:
received:
22
07
2021
revised:
31
01
2022
accepted:
17
02
2022
pubmed:
18
2
2022
medline:
24
6
2022
entrez:
17
2
2022
Statut:
ppublish
Résumé
The relationship between antidepressant response and glial, inflammatory, and metabolic markers is poorly understood in depression. This study assessed the ability of biological markers to predict antidepressant response in major depressive disorder (MDD). We included 31 MDD outpatients treated with escitalopram or sertraline for 8 consecutive weeks. The Montgomery-Åsberg Depression Rating Scale (MADRS) was administered at baseline and at week 4 and 8 of treatment. Concomitantly, blood samples were collected for the determination of serum S100B, C-reactive protein (CRP), and high-density lipoprotein cholesterol (HDL)-C levels. Treatment response was defined as ≥50% improvement in the MADRS score from baseline to either week 4 or 8. Variables associated with treatment response were included in a linear regression model as predictors of treatment response. Twenty-seven patients (87%) completed 8 weeks of treatment; 74% and 63% were responders at week 4 and 8, respectively. High S100B and low HDL-C levels at baseline were associated with better treatment response at both time points. Low CRP levels were correlated with better response at week 4. Multivariate analysis showed that high baseline S100B levels and low baseline HDL-C levels were good predictors of treatment response at week 4 (R2 = 0.457, P = .001), while S100B was at week 8 (R2 = 0.239, P = .011). Importantly, baseline S100B and HDL-C levels were not associated with depression severity and did not change over time with clinical improvement. Serum S100B levels appear to be a useful biomarker of antidepressant response in MDD even when considering inflammatory and metabolic markers.
Sections du résumé
BACKGROUND
The relationship between antidepressant response and glial, inflammatory, and metabolic markers is poorly understood in depression. This study assessed the ability of biological markers to predict antidepressant response in major depressive disorder (MDD).
METHODS
We included 31 MDD outpatients treated with escitalopram or sertraline for 8 consecutive weeks. The Montgomery-Åsberg Depression Rating Scale (MADRS) was administered at baseline and at week 4 and 8 of treatment. Concomitantly, blood samples were collected for the determination of serum S100B, C-reactive protein (CRP), and high-density lipoprotein cholesterol (HDL)-C levels. Treatment response was defined as ≥50% improvement in the MADRS score from baseline to either week 4 or 8. Variables associated with treatment response were included in a linear regression model as predictors of treatment response.
RESULTS
Twenty-seven patients (87%) completed 8 weeks of treatment; 74% and 63% were responders at week 4 and 8, respectively. High S100B and low HDL-C levels at baseline were associated with better treatment response at both time points. Low CRP levels were correlated with better response at week 4. Multivariate analysis showed that high baseline S100B levels and low baseline HDL-C levels were good predictors of treatment response at week 4 (R2 = 0.457, P = .001), while S100B was at week 8 (R2 = 0.239, P = .011). Importantly, baseline S100B and HDL-C levels were not associated with depression severity and did not change over time with clinical improvement.
CONCLUSIONS
Serum S100B levels appear to be a useful biomarker of antidepressant response in MDD even when considering inflammatory and metabolic markers.
Identifiants
pubmed: 35176771
pii: 6530347
doi: 10.1093/ijnp/pyac016
pmc: PMC9211008
doi:
Substances chimiques
Antidepressive Agents
0
Biomarkers
0
S100 Calcium Binding Protein beta Subunit
0
S100B protein, human
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
468-478Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of CINP.
Références
Curr Drug Targets. 2013 Oct;14(11):1225-36
pubmed: 23469922
J Affect Disord. 2005 Dec;89(1-3):25-33
pubmed: 16263178
Brain Behav Immun. 2019 Feb;76:215-222
pubmed: 30476563
Eur Neuropsychopharmacol. 2021 Apr;45:89-107
pubmed: 33386229
Neuropsychopharmacology. 2017 Jan;42(1):115-128
pubmed: 27402495
Brain Res. 2015 Aug 18;1617:113-25
pubmed: 25003554
J Neurochem. 2019 Jan;148(2):168-187
pubmed: 30144068
Nord J Psychiatry. 2018 Oct;72(7):462-470
pubmed: 29764272
Brain Behav Immun. 2020 Aug;88:908-912
pubmed: 31972338
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1557-61
pubmed: 18583011
J Clin Psychiatry. 2017 Jan;78(1):e1-e7
pubmed: 28129497
PLoS One. 2014 Jul 02;9(7):e101477
pubmed: 24988410
Psychoneuroendocrinology. 2017 Apr;78:105-113
pubmed: 28187400
Eur Neuropsychopharmacol. 2020 Dec;41:40-51
pubmed: 32980240
Psychol Med. 2019 Sep;49(12):1958-1970
pubmed: 31258105
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Curr Opin Lipidol. 2016 Oct;27(5):521-30
pubmed: 27495134
Science. 2001 Nov 9;294(5545):1354-7
pubmed: 11701931
J Neural Transm (Vienna). 2014 Nov;121(11):1411-5
pubmed: 24801966
Int J Mol Sci. 2018 Jan 12;19(1):
pubmed: 29329256
Psychoneuroendocrinology. 2018 May;91:55-61
pubmed: 29525586
J Biol Chem. 2000 Dec 22;275(51):40096-105
pubmed: 11007787
Pharmaceuticals (Basel). 2019 Dec 17;12(4):
pubmed: 31861074
Int J Neuropsychopharmacol. 2015 Sep 12;19(3):pyv103
pubmed: 26364276
J Neuroinflammation. 2013 Dec 01;10:142
pubmed: 24289502
Neuropharmacology. 2020 Aug 15;173:108158
pubmed: 32464133
Psychiatry Res. 2016 Jan 30;235:38-42
pubmed: 26677733
Psychoneuroendocrinology. 2019 Dec;110:104414
pubmed: 31493698
BMC Med. 2013 May 15;11:129
pubmed: 23672628
Eur Neuropsychopharmacol. 2003 Aug;13(4):235-9
pubmed: 12888182
Brain Behav Immun. 2011 Aug;25(6):1233-41
pubmed: 21447379
J ECT. 2006 Sep;22(3):206-12
pubmed: 16957538
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
Psychopharmacology (Berl). 2005 Mar;178(2-3):161-6
pubmed: 15316717
Psychiatry Clin Neurosci. 2010 Jun;64(3):279-83
pubmed: 20374538
Brain Behav Immun. 2021 Mar;93:331-334
pubmed: 33378714
Biol Psychiatry. 2013 Jun 15;73(12):1172-9
pubmed: 23726152
J Affect Disord. 2008 Dec;111(2-3):271-80
pubmed: 18430474
World J Biol Psychiatry. 2012 Oct;13(7):482-92
pubmed: 21707463
J Affect Disord. 2001 Sep;66(1):89-93
pubmed: 11532538
Lipids Health Dis. 2019 Mar 18;18(1):65
pubmed: 30885233
Med Clin (Barc). 2002 Apr 13;118(13):493-9
pubmed: 11975886
Neuropsychopharmacology. 2014 Jun;39(7):1624-34
pubmed: 24442097
Arch Gen Psychiatry. 1976 Jun;33(6):766-71
pubmed: 938196
Neurosci Lett. 2008 Aug 29;441(3):291-5
pubmed: 18588943
Biol Psychiatry. 2010 Mar 15;67(6):543-9
pubmed: 20044070
J Neuroimmunol. 2007 Mar;184(1-2):214-22
pubmed: 17254641
Psychol Med. 2018 May;48(7):1102-1110
pubmed: 28889804
J Neurochem. 2012 Mar;120(5):644-59
pubmed: 22145907
Eur Neuropsychopharmacol. 2021 Apr;45:108-121
pubmed: 33189523
Eur Neuropsychopharmacol. 2021 Jan;42:35-44
pubmed: 33191075
J Neurotrauma. 2013 Apr 1;30(7):519-28
pubmed: 23297751
Neuroreport. 2002 Sep 16;13(13):1675-8
pubmed: 12352625
Psychoneuroendocrinology. 2017 Oct;84:206
pubmed: 28449941
CNS Neurosci Ther. 2016 Mar;22(3):248-50
pubmed: 26848720
Clin Chim Acta. 2001 Aug 20;310(2):173-86
pubmed: 11498083
Curr Top Behav Neurosci. 2017;31:31-44
pubmed: 27221626
Dis Markers. 2018 Jan 10;2018:2358451
pubmed: 29545905
Transl Psychiatry. 2020 May 21;10(1):161
pubmed: 32439851
Sports Med. 2014 Mar;44(3):369-85
pubmed: 24194479
World J Biol Psychiatry. 2015 Feb;16(2):106-13
pubmed: 25264292
Neurosci Lett. 2012 Nov 7;529(2):139-43
pubmed: 22982200
Lipids Health Dis. 2018 Jan 03;17(1):1
pubmed: 29298716
Cell Mol Neurobiol. 2021 Oct 12;:
pubmed: 34637015
Neuropsychobiology. 2009;59(3):172-7
pubmed: 19468240
Psychiatry Investig. 2008 Sep;5(3):193-8
pubmed: 20046365